Identification of Inhibitors of human Galactokinase (GALK) for the treatment of Galactosemia

在此期间，NCGC继续进行其正在进行的药物化学活动，以提高Galk抑制活性。感兴趣的化合物已经被推进到基于细胞的分析和动物模型中，以进一步表征它们的细胞活性。 作为一个中心，NCGC与NIH和校外调查人员建立并保持了110多个积极的合作，促进了人类疾病整个谱系的药物发现工作。这些努力导致了数十个高通量筛选和许多药物化学活动，以进一步改进筛选命中，为我们的合作者和一般研究社区提供出版物和各种有前途的小分子探针和线索。此外，NCGC还致力于推进多项信息学倡议，以更好地利用现有的药物和疾病目标信息，并向公众提供易于获取的资源，进一步促进人类疾病新疗法的开发。

During this period, the NCGC continued with its ongoing medicinal chemistry campaign to improve GALK inhibitory activity. Compounds of interest have been advanced into cell-based assays and animal models to further characterize their cellular activity. As a center, the NCGC has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.